851333-14-7
851333-14-7 structure
- Name: EMD527040
- Chemical Name: EMD527040
- CAS Number: 851333-14-7
- Molecular Formula: C29H32Cl2N4O5
- Molecular Weight: 587.49
- Catalog: Signaling Pathways Cytoskeleton Integrin
- Create Date: 2021-09-05 18:04:47
- Modify Date: 2024-01-09 17:05:38
-
EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research[1].
| Name | EMD527040 |
|---|
| Description | EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research[1]. |
|---|---|
| Related Catalog | |
| Target |
αvβ6:6 nM (IC50) |
| In Vitro | EMD527040 inhibits binding of recombinant αvβ6 to fibronectin at 6 nM as compared to >9.5 μM for αvβ3 and αvβ5 integrins (IC5050)[1]. EMD527040 inhibits the attachment of αvβ6 expressing cells (UCLAP3 cells) to fibronectin at IC50 of 1.6 μM, as compared to >50 μM for αvβ3 and αvβ5 integrins[1]. |
| In Vivo | EMD527040 (intraperitoneal injection; 20-60 mg/kg; week 2 to 6 after BDL) attenuates bile ductular proliferation and peribiliary collagen deposition by 40-50%, induces downregulation of fibrogenic and upregulation of fibrolytic genes, and improves liver architecture and function. EMD527040 significantly reduced liver and spleen weights by 22% and 50%, respectively in Mdr2(Abcb4)-/- mice[1]. Animal Model: Male adult Wistar rats Dosage: 20-60 mg/kg Administration: Intraperitoneal injection; 20-60 mg/kg; week 2 to 6 after BDL (bile duct ligation) Result: Ameliorated fibrosis progression in rodents with biliary fibrosis. |
| References |
| Molecular Formula | C29H32Cl2N4O5 |
|---|---|
| Molecular Weight | 587.49 |